Welcome to our dedicated page for Structure Therapeutics ADR SEC filings (Ticker: GPCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a clinical-stage biotech’s disclosures can feel like a full-time job. Structure Therapeutics� reports are packed with GPCR science, clinical trial nuances and dilution math that few investors have time to untangle. That’s why this page offers Structure Therapeutics SEC filings explained simply—so you can move past technical jargon and focus on the signals that matter.
Stock Titan’s AI reads every new document the moment it hits EDGAR and produces clear summaries you can trust. Need the Structure Therapeutics quarterly earnings report 10-Q filing translated into plain English? Wondering which risk factors changed in the latest 10-K? Our engine highlights R&D burn, cash runway and trial milestones in a click. You’ll also find real-time alerts for Structure Therapeutics Form 4 insider transactions real-time, giving you immediate insight into executive conviction. Looking for strategic shifts? The platform tags each Structure Therapeutics 8-K material events explained entry so you can understand partnership news or study results without combing through pages.
Use the table below to scan every form, from the Structure Therapeutics annual report 10-K simplified to the Structure Therapeutics proxy statement executive compensation. Track Structure Therapeutics insider trading Form 4 transactions, compare segments across quarters, and explore Structure Therapeutics earnings report filing analysis before making your next move. Whether you’re monitoring Structure Therapeutics executive stock transactions Form 4 or simply understanding Structure Therapeutics SEC documents with AI, our platform delivers all filings—plus AI-powered commentary—so you spend less time reading and more time deciding.
FMR LLC, identified as a 10% owner of Structure Therapeutics Inc. (GPCR), filed a Form 4 reporting an open-market sale on 07/30/2025.
- Securities sold: 26,310 American Depositary Shares (ADS), each representing three ordinary shares.
- Sale price: $17.87 per ADS, implying cash proceeds of roughly $470 k.
- Post-sale indirect holdings: 1,515,558 ADS plus 575,934 ordinary shares (45,120 held by F-Prime Capital Partners Life Sciences Advisors Fund VI LP and 530,814 held by F-Prime Capital Partners Life Sciences Fund VI LP).
- The filing notes that Abigail P. Johnson is a director, Chairman and CEO of FMR LLC and that members of the Johnson family collectively control 49% of FMR’s voting power.
No acquisitions were reported; the sole transaction was the ADS disposition coded “S.� FMR and its affiliated funds remain above the 10% beneficial-ownership threshold.
FAQ
What is the current stock price of Structure Therapeutics ADR (GPCR)?
What is the market cap of Structure Therapeutics ADR (GPCR)?
